~~<i id='2D2F84D20E'><strike id='2D2F84D20E'><tt id='2D2F84D20E'><pre id='2D2F84D20E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：explore 2025-10-02 09:21:57 - browse：157

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

explore

Wikipedia

hotspot

entertainment

knowledge

KatiePalmer,STAT(left)moderatingtheDoctorvs.ChatGPTsessionduringthe2023STATSummit.STATGenerativeAIto

WSS

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

FDA clears Verve to begin U.S. study of gene

STAT Summit: Meghan O’Rourke on making chronic illness visible

hotspot

entertainment

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Moonlake's readout produced a cash windfall. Risks remain

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Cancer drug shortages should be causing more outrage

J&J lung cancer data amount to new salvo against AstraZeneca

State Dept. review finds Biden bears some blame for Afghanistan failures

Questions loom on AstraZeneca cancer drug as safety concerns ebb

BioMarin wins approval for gene therapy to treat hemophilia A

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

explore

Mississippi candidates for statewide offices square off in party primaries

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

STAT Readout Newsletter: Biotech news today

STAT Summit: Meghan O’Rourke on making chronic illness visible

ADCs take center stage as promising cancer treatments

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Wikipedia

hotspot

entertainment

knowledge